Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Kynexis

News headline image
Kynexis Announces First Patient Dosed in Phase 2 Clinical Trial of KYN-5356 for Cognitive Impairment Associated With Schizophrenia
From Kynexis
Via GlobeNewswire
News headline image
Kynexis Announces Positive Topline Results from Phase 1 Study of KYN-5356, a Potential Treatment for Cognitive Impairment Associated with Schizophrenia
From Kynexis
Via GlobeNewswire
News headline image
Kynexis Appoints Esteemed Scientific Advisory Board Members to Advance Precision Therapeutics for Brain Diseases
From Kynexis
Via GlobeNewswire
News headline image
Kynexis Announces Initiation of First-in-Human Phase 1 Study of KYN-5356, a Potential Treatment for Cognitive Impairment Associated with Schizophrenia
From Kynexis
Via GlobeNewswire
News headline image
Kynexis Launched to Advance Precision Therapeutics for Brain Diseases
From Kynexis
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.